Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Depreciation and Depletion: 2021-2024

Historic Depreciation and Depletion for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $904,000.

  • Amylyx Pharmaceuticals' Depreciation and Depletion fell 45.70% to $120,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $577,000, marking a year-over-year decrease of 44.78%. This contributed to the annual value of $904,000 for FY2024, which is 16.91% down from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Depreciation and Depletion stood at $904,000 for FY2024, which was down 16.91% from $1.1 million recorded in FY2023.
  • Amylyx Pharmaceuticals' Depreciation and Depletion's 5-year high stood at $1.1 million during FY2023, with a 5-year trough of $52,000 in FY2021.
  • In the last 3 years, Amylyx Pharmaceuticals' Depreciation and Depletion had a median value of $904,000 in 2024 and averaged $826,333.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first surged by 836.54% in 2022, then dropped by 16.91% in 2024.
  • Over the past 4 years, Amylyx Pharmaceuticals' Depreciation and Depletion (Yearly) stood at $52,000 in 2021, then surged by 836.54% to $487,000 in 2022, then spiked by 123.41% to $1.1 million in 2023, then dropped by 16.91% to $904,000 in 2024.